FindMyKOL
Clinical trialNCT05096715RecruitingPhase 1Interventional

Atezolizumab+Bevacizumab+SBRT in Unresectable HCC

SponsorMassachusetts General HospitalEnrollment20Unresectable Hepatocellular Carcinoma
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This research study is evaluating the safety and tolerability of the drugs atezolizumab and bevacizumab with stereotactic body radiation therapy (SBRT) for treating unresectable hepatocellular carcinoma. This study involves the following interventions: * Atezolizumab * Bevacizumab * Stereotactic body radiation therapy (SBRT)
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, United States

    Matthew Abrams, MD
    Not, yet, recruiting
  • Dana-Farber Cancer Institute

    Boston, Massachusetts, United States

    Harvey Mamon, MD, PhD
    Recruiting
  • Massachusetts General Hospital Cancer Center

    Boston, Massachusetts, United States

    Jennifer Y Wo, MD
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Atezolizumab →Bevacizumab →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
23 Aug 2022
Primary completion
31 Jan 2027
Completion
31 Jan 2032
Last update posted
18 Feb 2026
Registered enrollment
20
Registry id
NCT05096715
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.